These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38864249)

  • 1. Exploration of the sensitization effect of Chaihu Shugan powder on chemotherapy for triple-negative breast cancer and its active ingredients.
    Wei W; Li X; Li Z
    Biopolymers; 2024 Sep; 115(5):e23605. PubMed ID: 38864249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unveiling the Mechanism of the ChaiShao Shugan Formula Against Triple-Negative Breast Cancer.
    Fan T; Huang Y; Liu Z; Huang J; Ke B; Rong Y; Qiu H; Zhang B
    Drug Des Devel Ther; 2024; 18():1115-1131. PubMed ID: 38618280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated network pharmacology and experimental verification to explore the potential mechanism of San Ying decoction for treating triple-negative breast cancer.
    Yang X; Li F; Shi Y; Wu Y; Yang R; Liu X; Zhang Y; Zhang G; Ma M; Luo Z; Han X; Xie Y; Liu S
    Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):763-775. PubMed ID: 38516703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Molecular Mechanisms of Ephedra Herb in the Treatment of Nephrotic Syndrome Based on Network Pharmacology and Molecular Docking.
    Yao T; Wang Q; Han S; Lu Y; Xu Y; Wang Y
    Biomed Res Int; 2022; 2022():9214589. PubMed ID: 35837376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Potential Molecular Mechanism of the Shugan Jieyu Capsule in the Treatment of Depression through Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.
    Liu Z; Huang H; Yu Y; Jia Y; Li L; Shi X; Wang F
    Curr Comput Aided Drug Des; 2024; 20(5):501-517. PubMed ID: 37340752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quercetin and taxifolin inhibits TMPRSS2 activity and its interaction with EGFR in paclitaxel-resistant breast cancer cells: An in silico and in vitro study.
    Kundrapu DB; Chaitanya AK; Manaswi K; Kumari S; Malla R
    Chem Biol Drug Des; 2024 Aug; 104(2):e14600. PubMed ID: 39075030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
    Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
    Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the mechanism by which quercetin re-sensitizes breast cancer to paclitaxel: network pharmacology, molecular docking, and experimental verification.
    Yang Y; Yan J; Huang J; Wu X; Yuan Y; Yuan Y; Zhang S; Mo F
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3045-3059. PubMed ID: 37148401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the mechanism of action of Yiyi Fuzi Baijiang powder in colorectal cancer based on network pharmacology and molecular docking studies.
    Yan H; Li Y; Yang B; Long F; Yang Z; Tang D
    Biotechnol Genet Eng Rev; 2023 Oct; 39(2):1107-1127. PubMed ID: 36735641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network Pharmacology, Molecular Docking and Experimental Verification Revealing the Mechanism of Fule Cream against Childhood Atopic Dermatitis.
    Liu C; Liu Y; Liu Y; Guan J; Gao Y; Ou L; Qi Y; Lv X; Zhang J
    Curr Comput Aided Drug Des; 2024; 20(6):860-875. PubMed ID: 37807411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network pharmacology and experimental validation to explore the role and potential mechanism of Liuwei Dihuang Decoction in prostate cancer.
    Zhan X; Li H; Jin J; Ju X; Gao J; Chen X; Yuan F; Gu J; Xu D; Ju G
    BMC Complement Med Ther; 2024 Jul; 24(1):284. PubMed ID: 39061044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening of the multi-gene regulatory molecular mechanism of Si-Wu-tang against non-triple-negative breast cancer based on network pharmacology combined with experimental validation.
    Zhang Z; Liu J; Liu Y; Shi D; He Y; Zhao P
    J Ethnopharmacol; 2021 Apr; 269():113696. PubMed ID: 33358854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma.
    Yang Z; Liu H; Song Y; Gao N; Gao P; Hui Y; Li Y; Fan T
    Int J Mol Med; 2024 Sep; 54(3):. PubMed ID: 38994756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
    Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
    Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanism of Epimedium in the treatment of coronary atherosclerotic heart disease based on network pharmacology, molecular docking, and in vitro studies.
    Xin G; Yuedong Y; Xuemei S; Chenhan M; Meng Z; Chenbo Z; Ning G; Xindong W
    Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2478-2488. PubMed ID: 35442463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking.
    Li Y; Liu B; Liu L; Xu Q; Shen Q; Li W; Zhao J
    Medicine (Baltimore); 2022 Aug; 101(32):e29654. PubMed ID: 35960089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating GEO, network pharmacology, and in vitro assays to explore the pharmacological mechanism of Bruceae Fructus against laryngeal cancer.
    Wu Z; Zhu Z; Fu L
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4165-4181. PubMed ID: 38032489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotective Mechanism and Active Compounds of
    Sun X; Zhu Y; Li F; Li M; Wan G
    Comput Math Methods Med; 2022; 2022():4338260. PubMed ID: 36213575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.